These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21150278)

  • 1. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
    Garrido G; Tikhomirov IA; Rabasa A; Yang E; Gracia E; Iznaga N; Fernández LE; Crombet T; Kerbel RS; Pérez R
    Cancer Biol Ther; 2011 Feb; 11(4):373-82. PubMed ID: 21150278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.
    Zhou Y; Goenaga AL; Harms BD; Zou H; Lou J; Conrad F; Adams GP; Schoeberl B; Nielsen UB; Marks JD
    Mol Cancer Ther; 2012 Jul; 11(7):1467-76. PubMed ID: 22564724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.
    Kearns JD; Bukhalid R; Sevecka M; Tan G; Gerami-Moayed N; Werner SL; Kohli N; Burenkova O; Sloss CM; King AM; Fitzgerald JB; Nielsen UB; Wolf BB
    Mol Cancer Ther; 2015 Jul; 14(7):1625-36. PubMed ID: 25911688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
    Reilly EB; Phillips AC; Buchanan FG; Kingsbury G; Zhang Y; Meulbroek JA; Cole TB; DeVries PJ; Falls HD; Beam C; Gu J; Digiammarino EL; Palma JP; Donawho CK; Goodwin NC; Scott AM
    Mol Cancer Ther; 2015 May; 14(5):1141-51. PubMed ID: 25731184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations.
    Berger C; Krengel U; Stang E; Moreno E; Madshus IH
    J Immunother; 2011 Sep; 34(7):550-5. PubMed ID: 21760527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.
    Bhuvaneswari R; Ng QF; Thong PS; Soo KC
    Oncotarget; 2015 May; 6(15):13487-505. PubMed ID: 25918252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo.
    Zhou C; Zhu L; Ji J; Ding F; Wang C; Cai Q; Yu Y; Zhu Z; Zhang J
    Curr Cancer Drug Targets; 2017; 17(1):89-97. PubMed ID: 27739365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells.
    González JE; Barquinero JF; Lee M; García O; Casaco A
    Cancer Biol Ther; 2012 Jan; 13(2):71-6. PubMed ID: 22231391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies.
    Diaz Miqueli A; Rolff J; Lemm M; Fichtner I; Perez R; Montero E
    Br J Cancer; 2009 Mar; 100(6):950-8. PubMed ID: 19293809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
    Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
    J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.
    Zhao L; Li QQ; Zhang R; Xi M; Liao YJ; Qian D; He LR; Zeng YX; Xie D; Liu MZ
    Tumour Biol; 2012 Aug; 33(4):1115-23. PubMed ID: 22389159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.
    Kurai J; Chikumi H; Hashimoto K; Takata M; Sako T; Yamaguchi K; Kinoshita N; Watanabe M; Touge H; Makino H; Igishi T; Hamada H; Yano S; Shimizu E
    Int J Oncol; 2012 Nov; 41(5):1610-8. PubMed ID: 22922885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs.
    James R; Vishwakarma S; Chivukula IV; Basavaraj C; Melarkode R; Montero E; Nair P
    Cancer Med; 2012 Oct; 1(2):114-27. PubMed ID: 23342262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of autophagy in cetuximab-mediated cancer therapy against EGFR.
    Li X; Lu Y; Pan T; Fan Z
    Autophagy; 2010 Nov; 6(8):1066-77. PubMed ID: 20864811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities.
    Diaz Miqueli A; Blanco R; Garcia B; Badia T; Batista AE; Alonso R; Montero E
    Hybridoma (Larchmt); 2007 Dec; 26(6):423-31. PubMed ID: 18158788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.
    Brockhoff G; Heckel B; Schmidt-Bruecken E; Plander M; Hofstaedter F; Vollmann A; Diermeier S
    Cell Prolif; 2007 Aug; 40(4):488-507. PubMed ID: 17635517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor.
    Emanuel SL; Engle LJ; Chao G; Zhu RR; Cao C; Lin Z; Yamniuk AP; Hosbach J; Brown J; Fitzpatrick E; Gokemeijer J; Morin P; Morse BA; Carvajal IM; Fabrizio D; Wright MC; Das Gupta R; Gosselin M; Cataldo D; Ryseck RP; Doyle ML; Wong TW; Camphausen RT; Cload ST; Marsh HN; Gottardis MM; Furfine ES
    MAbs; 2011; 3(1):38-48. PubMed ID: 21099371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.